Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07298473 · ClinicalTrials.gov registry record · NA
Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)
A NA study, sponsored by Medtronic Cardiac Ablation Solutions.
- Recruiting
- Registry status
- NA
- Development phase
- 400
- Enrollment target
NCT07298473 is a NA study that is actively recruiting participants, run by Medtronic Cardiac Ablation Solutions. The registered enrollment target is 400 participants.
The verdict
NCT07298473, a NA study, is actively recruiting participants, sponsored by Medtronic Cardiac Ablation Solutions.
- RECRUITING
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
Study Summary
Conquer-AF is a prospective, multi-center, interventional, non-randomized clinical study that will enroll up to 400 subjects at up to 30 sites across the United States, Europe, and Australia. Subjects diagnosed with symptomatic recurrent paroxysmal or persistent atrial fibrillation after a single prior ablation procedure will be enrolled in this study. Each subject will undergo a study index redo ablation procedure using the Sphere-9 Catheter and Affera Ablation System and will be followed for 12 months. The expected total study duration (from time of first enrollment to the exit of last enrolled subject) is approximately 2 years.
Interventions
- DEVICE Sphere-9 Catheter Ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2026-04-08 |
| Est. Completion | 2028-03-29 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07298473
The ClinicalTrials.gov registry entry for NCT07298473 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Ablation Solutions, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sphere-9 Catheter Ablation is the first listed.
NCT07298473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07298473 about?
NCT07298473 is a clinical study titled "Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)". Conquer-AF is a prospective, multi-center, interventional, non-randomized clinical study that will enroll up to 400 subjects at up to 30 sites across the United States, Europe, and Australia. Subjects diagnosed with symptomatic recurrent paroxysmal or persistent atrial fibrillation after a single p...
What is the current status of trial NCT07298473?
This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2026-04-08. Estimated completion is 2028-03-29.
What interventions are being tested in trial NCT07298473?
The interventions under investigation include: Sphere-9 Catheter Ablation (DEVICE).
Who is sponsoring clinical trial NCT07298473?
This trial is sponsored by Medtronic Cardiac Ablation Solutions, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.